Table 2.
Pre- and post-ELEVATE comparisons of tobacco use assessment and treatment among Siteman Cancer Center outpatients. ELEVATE is associated with significantly increased tobacco use assessment and documented treatment
| Timeframe of data collection (EHR) | Pre-ELEVATE (January 1, 2018–June 1, 2018, Allscripts TouchWorks) | Post-ELEVATE (June 2, 2018–October 31, 2018, Epic) | z | p |
|---|---|---|---|---|
| Patients seen, N | 34,223 | 24,485 | ||
| Tobacco use assessed, n (% of patients seen) | 16,382 (47.87%)a | 22,004 (89.87%) | 126.57 | <.001 |
| Current smokers, n (% of patients assessed) | 2,917a | 2,567 (11.67%) | ||
| Brief counseling provided, n (% of current smokers) | NA | 467 (18.19%) | ||
| Cessation counseling offered, n (% of current smokers) | NA | 527 (20.53%) | ||
| Cessation counseling provided or referred, n (% of current smokers) | 21 (0.72%) | 49 (1.91%) | 3.81 | <.001 |
| Cessation medication prescribed and/or documented, n (% of current smokers) | 89 (3.05%) | 434 (16.91%)b | 17.20 | <.001 |
EHR electronic health record; NA not available.
aThere was no accurate estimate of pre-ELEVATE smoking prevalence due to low assessment rates.
b125 (4.87%) smokers were prescribed and 280 (10.91%) smokers were documented as using cessation medication, with 29 (1.13%) smokers having both prescribed and documented medication.